Adaptive in Seattle Times


Adaptive Biotechnologies, a Seattle startup that focuses on scouring the genetic makeup of the immune system to help fight cancer and other diseases, said Monday it has raised an eye-popping $105 million in funding to boost its research and commercial efforts. Read full article at Times Website

Adaptive Biotechnologies Announces Completion of Series C and Series D Financing Rounds Through a $105 million Private Investment from Viking Global Investors

Original Founders of Adaptive

Adaptive announced today the completion of the Company’s Series C financing round and the completion of a newly created Series D round with a $105 million investment from Viking Global Investors.  This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.

Adaptive Announces a Biomarker Discovery Agreement with Johnson & Johnson Innovation


Adaptive announced today a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California.  Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQTM, to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The exploration of immune response may identify patient populations more likely to respond to targeted therapies based on their immune status.

Adaptive test featured on CBS News; highlighting STM publication


CBS News just published a story highlighting the promise of Adaptive’s QuanTILfy test that is being tested in many solid tumors for the prognosis, diagnosis, and monitoring of cancer patients. The article is based on a study published yesterday in Science Translational Medicine  demonstrating that QuanTILfy may help predict survival in ovarian cancer patients.